05th week of 2012 patent applcation highlights part 53 |
Patent application number | Title | Published |
20120028840 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 2012-02-02 |
20120028841 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 2012-02-02 |
20120028842 | GENETIC ANALYSIS LOC WITH HYBRIDIZATION ARRAY WITH POSITIVE CONTROL CHAMBERS INCORPORATING PROBES THAT HYBRIDIZE FOR ANY AMPLICON - A microfluidic device having a supporting substrate, an inlet for receiving a biological sample containing a target nucleic acid sequence, and, an array of probes each having a nucleic acid sequence for hybridization with the target nucleic acid sequence to form a probe-target hybrid, wherein, the array of probes includes a control probe for hybridization with a target sequence known to be always present in the biological sample. | 2012-02-02 |
20120028843 | Methods and Apparatuses for Chip-Based DNA Error Reduction - Methods and apparatus relate to reduction of sequence errors generated during synthesis of nucleic acids on a microarray chip. The error reduction can include synthesis of complementary stands (to template strands), using a short universal primer complementary to the template strands and polymerase. Heteroduplex can be formed be melting and re-annealing complementary stands and template strands. The heteroduplexes containing a mismatch can be recognized and cleaved by a mismatch endonuclease. The mismatch-containing cleaved heteroduplexes can be removed from the microarray chip using a global buffer exchange. The error free synthetic nucleic acids generated therefrom can be used for a variety of applications, including synthesis of biofuels and value-added pharmaceutical products. | 2012-02-02 |
20120028844 | REAGENT DISPENSERS AND STACKABLE BARS FOR MULTIPLEX BINDING ASSAYS - Multiplex binding assay assemblies are disclosed. The assemblies generally include at least one assay bar that includes a top side, a bottom side, and at least one well accessible from the top side of the assay bar. Each well includes a side surface, a bottom surface, an open top end, and at least one secondary container, with each secondary container including a capillary tube that (i) begins at a location within an interior volume of the well and (ii) ends at a location beneath the bottom surface of the assay bar. The assemblies further include a dispenser bar that is adapted to be positioned adjacent to the top side of the assay bar, which includes one or more reservoirs that are configured to provide one or more reagents to the at least one secondary container located in each well of the assay bar. | 2012-02-02 |
20120028845 | Sensor for Detecting Biological Agents in Fluid - Systems and apparatus are disclosed for detecting biological agents in fluids. Biosensor apparatus utilizes a sample chamber configured for receiving a fluid sample. Wells accessible from the sample chamber include electrodes deployed for receiving one or more electromagnetic signal from each of the wells. The electrodes are pre-provided with biomaterial deposits selected to attract particular biological agents of interest. An integrated circuit connected with electrodes facilitates electromagnetic signal acquisition and processing of parameters measurable at the well electrodes. | 2012-02-02 |
20120028846 | GAS SENSOR INCORPORATING A POROUS FRAMEWORK - The disclosure provides sensor for gas sensing including CO | 2012-02-02 |
20120028847 | ASSEMBLIES FOR MULTIPLEX ASSAYS - Multiplex binding assay assemblies are disclosed. The assemblies include at least one assay bar that has a top side, a bottom side, and at least one well accessible from the top side of the assay bar, with each well including a side surface, a bottom surface, an open top end. Each well also includes at least one secondary container, with each secondary container including a capillary tube that (i) begins at a location within an interior volume of the well and (ii) ends at a location beneath the bottom side of the assay bar. The assemblies further include a guiding track, which includes a set of two rails, with each rail having its own separate groove. Such grooves are configured to run parallel to each other with a distance between such grooves, with a first groove configured to receive a protruding element (or an end) of a first side of the assay bar, and a second groove configured to receive a protruding element (or an end) of a second side of the assay bar. The set of two separate grooves are configured to allow the assay bar to glide along the grooves from one side to a second side of the guiding track. | 2012-02-02 |
20120028848 | Binding method and apparatus for sorting objects - The present invention relates to a method and apparatus of sorting objects including, providing a sample having wanted objects and unwanted objects; coating a surface of a sample holder with an antibody; placing an eluted sample on the sample holder; binding an antigen in the wanted objects with the antibody on the surface of the sample holder to sort the objects into wanted objects and unwanted objects; separating the wanted objects; and performing PCR-based STR analysis on the wanted objects. In one embodiment, holographic optical trapping is used to further sort the wanted objects. In other embodiments, the wanted objects are sperm and the antibody is a human sperm specific antibody, and the PCR is single cell PCR-based STR analysis. In still other embodiments, the binding is direct or indirect, ligands are used to bind to object-specific organomolecules, and protein A or protein G are used to bind the antibody. | 2012-02-02 |
20120028849 | MICROWAVE ACCELERATED ASSAYS - The present invention provides for increasing fluorescence detection in surface assay systems while increasing kinetics of a bioreaction therein by providing low-power microwaves to irradiate metallic materials within the system in an amount sufficient to increase heat thereby affecting the kinetics of a bioreaction therein. | 2012-02-02 |
20120028850 | MICROFLUIDIC DEVICE FOR SIMULTANEOUSLY CONDUCTING MULTIPLE ANALYSES - Provided is a rotatable microfluidic device for conducting simultaneously two or more assays. The device includes a platform which can be rotated, a first unit which is disposed at one portion of the platform and detects a target material from a sample using surface on which a capture probe selectively binds to the target material is attached, and a second unit which is disposed at another portion of the platform and detects a target material included in the sample by a different reaction from the reaction conducted in the first unit. | 2012-02-02 |
20120028851 | MICROFLUIDIC DEVICE FOR SIMULTANEOUSLY CONDUCTING MULTIPLE ANALYSES - Provided is a rotatable microfluidic device for conducting simultaneously two or more assays. The device includes a platform which can be rotated, a first unit which is disposed at one portion of the platform and detects a target material from a sample using surface on which a capture probe selectively binds to the target material is attached, and a second unit which is disposed at another portion of the platform and detects a target material included in the sample by a different reaction from the reaction conducted in the first unit. | 2012-02-02 |
20120028852 | MICROFLUIDIC DEVICE FOR SIMULTANEOUSLY CONDUCTING MULTIPLE ANALYSES - Provided is a rotatable microfluidic device for conducting simultaneously two or more assays. The device includes a platform which can be rotated, a first unit which is disposed at one portion of the platform and detects a target material from a sample using surface on which a capture probe selectively binds to the target material is attached, and a second unit which is disposed at another portion of the platform and detects a target material included in the sample by a different reaction from the reaction conducted in the first unit. | 2012-02-02 |
20120028853 | DRILLING FLUID, DRILLING FLUID ADDITIVE, METHODS OF MAKING AND USING, SUCH FLUID AND ADDITIVE, METHODS OF OPERATING A WELL - Well fluids and well fluid additives comprising a blend of guar gums of various viscosities, methods of making and using such fluids and additives, and methods of operating a well using such fluids and/or additives. | 2012-02-02 |
20120028854 | FLUID FOR DEEP OFFSHORE DRILLING - The disclosure relates to a drilling fluid having a viscosity at 40° C. less than or equal to 2.5 mm | 2012-02-02 |
20120028855 | SHALE HYDRATION INHIBITION AGENT(S) AND METHOD OF USE - A method of using water-based drilling fluid in a subterranean formation containing shale which swells in the presence of water by circulating a water-based drilling fluid into the formation. The drilling fluid is made of an aqueous based continuous phase, a weighting material, and a shale hydration inhibition agent (SHIA) comprising deep eutectic solvents (DES) formed by the reaction of a first compound comprising an ammonium compound, and a second compound comprising at least one of amides, amines, diamines, cyclic amines, cyclic diamines, and combinations thereof. The SHIA is present in an amount sufficient to reduce shale swelling. A method of reducing shale swelling during wellbore drilling that includes providing a water-based drilling fluid comprising an aqueous based continuous phase, a weighting material, and a SHIA comprising DES formed by the reaction of a quaternary ammonium compound, and a diamine; and circulating the drilling fluid into the subterranean formation. | 2012-02-02 |
20120028856 | COPOLYMER FOR INHIBITING INORGANIC DEPOSITS - The invention relates to a copolymer having:
| 2012-02-02 |
20120028857 | AUTOMOBILE TRANSMISSION OIL COMPOSITION WITH IMPROVED LOW-TEMPERATURE TRANSMISSION PERFORMANCE - The present invention provides a manual transmission oil composition containing a predetermined amount of polyalphaolefin (PAO) synthetic base oil and a predetermined amount of polyalkylmethacrylate having a number-average molecular weight of 300,000 to 400,000 as a viscosity index improver and thus having a high viscosity even at high temperatures and a low viscosity at low temperatures compared to other manual transmission oils having the same viscosity grade (SAE 75W85 grade). | 2012-02-02 |
20120028858 | Process for the manufacture of functional PFPE derivative - A process for the manufacture of a functional (per)fluoropolyether derivative comprising at least one triazole group, such process comprising: (1) reacting a (per)fluoropolyether hydroxyl derivative having at least one hydroxyl group [derivative (PFPE-OH)] with an activating agent, to yield an activated (per)fluoropolyether hydroxyl derivative comprising at least one activated hydroxyl group [derivative (a-PFPE-OH)]; (2) reacting said activated (per)fluoropolyether hydroxyl derivative [derivative (a-PFPE-OH)] with at least one azide salt to yield a functional (per)fluoropolyether derivative comprising at least one azido group [derivative (PFPE-N | 2012-02-02 |
20120028859 | METHOD OF PREPARING GREASES - Provided is a method for preparing a grease composition, which comprises mixing an amine in a lubricating bas oil and an isocyanate in a lubricating base oil under high pressure and high flow rate impingement. In one embodiment, the mixing and reaction occurs in a reaction injection molding device. The resulting grease composition is an extremely low noise grease, being virtually clear of any urea thickener particles. | 2012-02-02 |
20120028860 | Method of Preparing Greases - Provided is a method for preparing a grease composition, which comprises mixing grease components under high pressure and high flow rate impingement. In one embodiment, a first mixture of an amine in a lubricating base oil is mixed with an isocyanate in a lubricating base oil under high pressure and high flow impingement. In another embodiment, the mixing and reaction occurs in a reaction injection molding device. The orifice size through which each of the mixtures is introduced into a reaction/mixing zone is less than 0.030 inch (0.0762 centimeter) in diameter. The resulting grease composition is an extremely low noise grease, being virtually clear of any urea thickener particles, and/or can exhibit good high temperature resistance and mechanical stability. | 2012-02-02 |
20120028861 | METHOD FOR IMPROVING THE DEPOSIT FORMATION RESISTANCE PERFORMANCE OF TURBINE OILS CONTAINING AMINE ANTIOXIDANTS - The deposit formation resistance performance of turbine oils containing amine antioxidants and antiwear additives is enhanced beyond the level of that of turbine oils containing tricresyl phosphate antiwear additive by employing as the antiwear additive a 4,4′-(Isopropylidenediphenyl)bis(diphenyl phosphate). | 2012-02-02 |
20120028862 | LOW VISCOSITY DIESEL ENGINE OIL COMPOSITION WITH IMPROVED FUEL EFFICIENCY - The present invention provides an engine oil composition containing polymethylacrylate, zinc alkyldithiophosphate, molybdenum dithiocarbamate, a hindered phenol antioxidant, and a fixed mineral oil. The engine oil composition of the present invention has a low-temperature viscosity The fuel efficiency of the engine oil is improved, when the engine oil composition with an improved low-temperature performance, a maintained high-temperature viscosity, an improved wear resistance, and an improved oxidation resistance is used. Further, the durability of the engine oil can also be ensured when the engine oil composition of the present invention is used. | 2012-02-02 |
20120028863 | APPLICATION-SPECIFIC FINISHED LUBRICANT COMPOSITIONS COMPRISING A BIO-DERIVED ESTER COMPONENT AND METHODS OF MAKING SAME - The present invention is generally directed to methods of making application-specific finished lubricant compositions comprising bio-derived diester species. In some embodiments, bio-derived fatty acid moieties are reacted with Fischer-Tropsch/gas-to-liquids reaction products and/or by-products (e.g., gas-to-liquids-produced α-olefins) to yield bio-derived diester species that can then be selectively blended with base oil and one or more additive species to yield an application-specific finished lubricant product having a biomass-derived component. | 2012-02-02 |
20120028864 | AZEOTROPIC AND AZEOTROPE-LIKE COMPOSITIONS OF METHYL PERFLUOROHEPTENE ETHERS AND ISO-PROPANOL AND USES THEREOF - The present disclosure provides azeotropic and azeotrope-like compositions comprised of methylperfluoroheptene ethers and 2-propanol. The present disclosure also provides for methods of use for the azeotropic and azeotrope-like compositions. | 2012-02-02 |
20120028865 | Viscosity Modifiers Comprising Blends of Ethylene-Based Copolymers - The present invention is directed to polymer blend compositions for use as viscosity modifiers comprising at least three ethylene-based copolymer components. The viscosity modifiers described herein comprise a first ethylene-based copolymer having an ethylene content of from about 35 to about 55 wt % and/or a heat of fusion of from about 0 to about 30 J/g, a second ethylene-based copolymer having an ethylene content of from about 55 to about 85 wt % and/or a heat of fusion of from about 30 to about 50 J/g, and a third ethylene-based copolymer having an ethylene content of from about 65 to about 85 wt % and/or a heat of fusion of from about 40 to about 70 J/g. The invention is also directed to lubricant compositions comprising a lubricating basestock and a polymer blend as described herein. | 2012-02-02 |
20120028866 | Viscosity Modifiers Comprising Blends of Ethylene-Based Copolymers - The present invention is directed to polymer blend compositions for use as viscosity modifiers comprising at least two ethylene-based copolymer components. The viscosity modifiers described herein comprise a first ethylene-based copolymer having an ethylene content of from about 44 to about 52 wt % and/or a heat of fusion of from about 0 to about 15 J/g and a second ethylene-based copolymer having an ethylene content of from about 68 to about 75 wt % and/or a heat of fusion of from about 40 to about 65 J/g. The invention is also directed to lubricant compositions comprising a lubricating basestock and a polymer blend of the invention. | 2012-02-02 |
20120028867 | Ethylene Based Copolymer Compositions as Viscosity Modifiers and Methods for Making Them - Polymeric compositions and methods for making and using the same are provided. The polymeric composition can include a first ethylene-based copolymer and a second ethylene-based copolymer. The first ethylene-based copolymer can have a weight percent of ethylene-derived units based on a weight of the polymeric composition (E | 2012-02-02 |
20120028868 | REMOVAL OF METAL SALT-COMPRISING IONIC LIQUIDS FROM WORKPIECES AND RECYCLING OF SUCH LIQUIDS - The present invention relates to a method of removing residues of a metal salt comprising ionic liquid—from a workpiece, which comprises the step
| 2012-02-02 |
20120028869 | CLEANSING IMPLEMENT - A cleansing implement comprising a generally planar compressed, water-swellable matrix and a solid cleansing composition coated on one face of the compressed matrix, the solid cleansing composition comprising an encapsulated perfume. | 2012-02-02 |
20120028870 | NON-AMINE POST-CMP COMPOSITION AND METHOD OF USE - A cleaning composition and process for cleaning post-chemical mechanical polishing (CMP) residue and contaminants from a microelectronic device having said residue and contaminants thereon. The cleaning compositions are substantially devoid of amine and ammonium-containing compounds, e.g., quaternary ammonium bases. The composition achieves highly efficacious cleaning of the post-CMP residue and contaminant material from the surface of the microelectronic device without compromising the low-k dielectric material or the copper interconnect material. | 2012-02-02 |
20120028871 | STRIPPING COMPOSITIONS FOR CLEANING ION IMPLANTED PHOTORESIST FROM SEMICONDUCTOR DEVICE WAFERS - A composition for removal of high dosage ion implanted photoresist from the surface of a semiconductor device, the composition having at least one solvent having a flash point >65° C., at least one component providing a nitronium ion, and at least one phosphonic acid corrosion inhibitor compound, and use of such a composition to remove high dosage ion implanted photoresist from the surface of a semiconductor device. | 2012-02-02 |
20120028872 | LIQUID DETERGENT COMPOSITION - A method of cleaning dishware with a liquid detergent composition having a hydrophobic emollient and a crystalline structurant to provide improved hand skin care benefits and superior grease cleaning and/or suds mileage. | 2012-02-02 |
20120028873 | LIQUID DETERGENT COMPOSITION - A dishwashing composition comprising a hydrophobic emollient and an enzyme, preferably a protease, to provide improved hand skin care benefits and superior cleaning and/or suds mileage. | 2012-02-02 |
20120028874 | PARTICLES - The present application relates to particles comprising a benefit agent encapsulated by a first layer that is in turn encapsulated by a second material, and products comprising such particles, as well as processes for making and using such particles and products comprising such particles. The process of making such particles does not unduly degrade the benefit agent and when such particles are employed in a product, they are stable, yet they release the desired amount of benefit agent when such product is used as intended. | 2012-02-02 |
20120028875 | MICROEMULSION LIQUID CLEANING COMPOSITIONS - A liquid cleaning composition having a base comprising an inert liquid, approximately 10-40% by weight of at least one cleaning component selected from the group of cleaning components comprising d-limonene, dibasic esters, heptanes and other paraffins, isoparaffins, isopraffinic mixtures, and aromatic solvents, approximately 5-20% by weight of a first co-surfactant, and approximately 1-20% by weight of a second co-surfactant. | 2012-02-02 |
20120028876 | STABILITY ENHANCEMENT AGENT FOR SOLID DETERGENT COMPOSITIONS - A stability enhancement agent for use in a solid detergent and solid detergent compositions is described. Stability enhancement is provided by a hydratable salt, water and a polyepoxysuccinic acid or polyepoxysuccinic acid metal salt binding agent forming a dimensionally stable composition. Preferred polyepoxysuccinic acid or polyepoxysuccinic acid metal salts have a molecular weight of between about 400 and about 1,500 g/mol. The stability enhancement composition for use in a solid detergent and solid detergent compositions are preferably biodegradable and substantially free of phosphorus and NTA. | 2012-02-02 |
20120028877 | Self-Buffering Protein Formulations - The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects. | 2012-02-02 |
20120028878 | Membrane Evaporation for Generating Highly Concentrated Protein Therapeutics - The present invention relates to methods of generating highly concentrated protein solutions, e.g., an antibody solution, a therapeutic protein solution, etc. The methods of the invention include membrane evaporation, such as evaporation of protein-free solvent from the protein solution, which concentrates the protein. The methods of the present invention result in protein solution concentrations not previously achievable by conventional ultrafiltration methods, e.g., protein solution concentrations of greater than about 260 grams of protein per liter of solution. | 2012-02-02 |
20120028879 | HIGHLY SENSITIVE DETECTION METHOD FOR HIGHLY VIRULENT ORAL CAVITY BACTERIA - Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of the hemolysis aggravation in a subject is assessed if a PA is not detected anchor a CBP is detected in the sample. Also provided are a detection reagent and kit for use in the method. | 2012-02-02 |
20120028880 | VEGFR-1/NRP-1 TARGETING PEPTIDES - The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly | 2012-02-02 |
20120028881 | METHODS AND REAGENTS FOR DIAGNOSING ATHEROMA - The invention provides a method of diagnosing atheroma in an individual, the method comprising providing a sample from the individual, determining the level of lysozyme in the sample and assessing whether the level is indicative of atheroma in the individual. The invention also provides the use of a reagent which selectively identifies lysozyme in the assessment of atheroma in an individual. | 2012-02-02 |
20120028882 | METHOD FOR REMOVING ENDOTOXIN FROM PROTEINS - Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing. | 2012-02-02 |
20120028883 | COMPLEX AND PRODUCTION PROCESS - A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of α-lactalbumin, such as human α-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has cysteines found in the native protein changed to other amino acids, such as alanine. Improvements in recombinant expression, process rationalisation and yields of biologically active complexes, as well as the complexes obtained are also described and claimed. | 2012-02-02 |
20120028884 | ANTIFUNGAL PAINTS AND COATINGS - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2012-02-02 |
20120028885 | ANTIFUNGAL PAINTS AND COATINGS - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2012-02-02 |
20120028886 | ANTIFUNGAL PAINTS AND COATINGS - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2012-02-02 |
20120028887 | LIPOPEPTIDE INHIBITORS OF HIV-1 - The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety possesses anti-fusogenic activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV. | 2012-02-02 |
20120028888 | APJ RECEPTOR COMPOUNDS - The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection. | 2012-02-02 |
20120028889 | INTEGRASE COFACTOR - The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules. | 2012-02-02 |
20120028890 | ACID CONTAINING LIPID FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations. | 2012-02-02 |
20120028891 | METHODS OF PROMOTING OR MAINTAINING AN ANABOLIC STATE IN A FEMALE ANIMAL - The present invention is related to methods of promoting or maintaining an anabolic state in a female animal. The methods comprise administering a composition to the female animal, with the composition comprising between about 15% to about 25% protein (w/w) and about 5% to about 15% fat (w/w). The protein source in the composition comprises chicken eggs and further comprises a second protein source selected from the group consisting of soybean meal and lamb meat | 2012-02-02 |
20120028892 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF - The invention is directed to a compound according to formula (I). The compounds of formula (I) include prodrugs, pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier and to methods for treating diabetes by administering such a pharmaceutical composition alone or in combination with other therapeutic agents. The invention is also directed to inhibitors of fructose-1,6-bisphosphatase. | 2012-02-02 |
20120028893 | Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses - Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects. | 2012-02-02 |
20120028894 | PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF - Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed. | 2012-02-02 |
20120028895 | Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment. | 2012-02-02 |
20120028896 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS - A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants. | 2012-02-02 |
20120028897 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS - Methods of treating fluid retention disorders with the B isomers of guanylin family peptides are described herein. UgnB, when compared to the A isomer (UgnA), exhibits a conventional sigmoidal dose-response relationship in its natriuetic activity. Further, unlike UgnA, UgnB only weakly activates the GC-C receptor. Compositions comprising purified, or mixtures containing B isomers of guanylin family peptides are described herein are therefore useful for the treatment of fluid retention disorders. | 2012-02-02 |
20120028898 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN - The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia. | 2012-02-02 |
20120028899 | COMPOSITION AND PROCESS FOR SYNTHESIZING TENSE AND RELAXED STATE POLYMERIZED HEMOGLOBIN - Described herein is a composition and process for synthesizing a hemoglobin-based oxygen carrier (HBOC) composition that includes a polymerized hemoglobin locked in at least one of the tense or relaxed quaternary state and has a molecular weight of at least about 500 kDa. The PolyHb may have a cross-linker to hemoglobin molar ratio of at least about 20:1. The polymerized hemoglobin is useful for delivering oxygen to cells, such as for treatment of anemic conditions in a subject, perfusion of tissues or organs, and supplementing cell culture media in cell culturing systems. | 2012-02-02 |
20120028900 | METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS - Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein. | 2012-02-02 |
20120028901 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound. | 2012-02-02 |
20120028902 | PEPTIDE AVAILABILITY - The present invention provides a process for producing a composition which is preferably a food, food intermediate, dietary supplement, feed or pet food, which comprises mixing together a peptide mixture, comprising a bioactive peptide, and a protein source having a protein quality (expressed as PER) of 2.4 or lower. The composition of the invention can be used to improve the bioavailability of bioactive peptides or used as a food, food intermediate, nutraceutical, dietary supplement, feed, or pet food. | 2012-02-02 |
20120028903 | MODULATION OF THE ACTIVITY AND DIFFERENTIATION OF CELLS EXPRESSING THE OSTEOCLAST-ASSOCIATED RECEPTOR - This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells. | 2012-02-02 |
20120028904 | METHODS, SYSTEMS, AND COMPOSITIONS FOR CALPAIN INHABITION - Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains. | 2012-02-02 |
20120028905 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A - Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed. | 2012-02-02 |
20120028906 | METHOD FOR AFFECTING THE TIMING OF CERVICAL RIPENING AND FOR PARTURITION - A method for affecting the timing of cervical ripening and the resultant onset of parturition in a pregnant female mammal, the method comprises administering to a pregnant female one or more than one dose of an agent that chemically mimics innervation of the cervix by the vagus nerve, thereby advancing the onset of parturition, or administering to a pregnant female one or more than one dose of an agent that chemically blocks innervation of the cervix by the vagus nerve, thereby delaying the onset of parturition. | 2012-02-02 |
20120028907 | METHODS FOR IDENTIFICATION OF TUMOR PHENOTYPE AND TREATMENT - The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a future date, methods of treating an ERGO tumor in a patient, and methods of selecting patients diagnosed as ERGO tumor prostate cancer patients for aggressive clinical treatment. The methods of the disclosure are applicable to ERGO tumors present in different human organs and tissues such as breast, lung, thyroid, ovary, and prostate. | 2012-02-02 |
20120028908 | Methods of Manufacturing Crystalline Forms of Rapamycin Analogs - A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split. | 2012-02-02 |
20120028909 | FN14/TRAIL Fusion Proteins - Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer, | 2012-02-02 |
20120028910 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS - Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. | 2012-02-02 |
20120028911 | Mucin Derived Polypeptides - The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or polynucleotides encoding the same alone or in combination along with a pharmaceutically acceptable carrier, diluent or excipient for the treatment of gastrointestinal disorders and diseases, including, irritable bowel disease and its associated colitides, for example, Crohn's Disease. | 2012-02-02 |
20120028912 | Methods of modulating bromodomains - The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease. | 2012-02-02 |
20120028913 | PEPTIDES FOR INHIBITING CHEMOKINE BINDING TO CHEMOKINE RECEPTORS - Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides. | 2012-02-02 |
20120028914 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTON PUMP INHIBITOR AND A PREBIOTIC FOR THE TREATMENT OF ULCEROUS LESIONS OF THE STOMACH AND DUODENUM - A pharmaceutical composition including proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of | 2012-02-02 |
20120028915 | 6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds. | 2012-02-02 |
20120028916 | COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES - The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition. | 2012-02-02 |
20120028917 | Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methy- l-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer - The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl) -1-phthalazinamine, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject. | 2012-02-02 |
20120028918 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME - The present invention relates to pharmaceutical compositions that include about 10 mg pazopanib/mL of the composition and about 2 to about 13% w/w of a modified cyclodextrin as well as methods of making the same are described. | 2012-02-02 |
20120028919 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS - The present invention provides a compound of formula I | 2012-02-02 |
20120028920 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS - A heterocyclic compound or a salt thereof represented by the formula (1): | 2012-02-02 |
20120028921 | METHODS AND COMPOSITIONS USING OXIDIZED PHOSPHOLIPIDS - The instant invention provides compositions, e.g., compositions comprising oxidized phospholipids, for the treatment of diseases, disorders and conditions, e.g., cute lung injury syndromes, sepsis, vascular leakage, edema, acute respiratory distress syndrome (ARDS) or acute inflammation. | 2012-02-02 |
20120028922 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 2012-02-02 |
20120028923 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds. | 2012-02-02 |
20120028924 | CHEMICAL COMPOUNDS - The present invention relates to compounds of Formula (I) and/or Formula (Ia): | 2012-02-02 |
20120028925 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2012-02-02 |
20120028926 | Phosphate Management with Small Molecules - This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels. | 2012-02-02 |
20120028927 | Novel Triazene Compounds For The Treatment Of Cancer - The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects. | 2012-02-02 |
20120028928 | Process for Isolating Tigecycline and Tigecycline Made Therefrom - The present invention provides a process for isolating tigecycline which process comprises the step of spray drying a solution of tigecycline in a solvent. Preferably the solvent is water or an organic solvent. In another aspect, there is provided tigecycline obtainable by spray drying, particularly in amorphous form. In particular, the invention provides tigecycline obtainable by spray drying according to the process of the invention. | 2012-02-02 |
20120028929 | TETRACYCLINE STABILIZING FORMULATIONS - An aqueous solution comprising a chelating agent at a concentration of about 0.1-0.5%, and an antioxidant agent at a concentration of about 0.1-0.5%, wherein the pH of the solution is between about 4.5 and about 7.5 is disclosed. The aqueous solution may comprise a tetracycline composition wherein the tetracycline is formulated in the aqueous solution. A method for reducing the rate and/or overall extent of degradation of a tetracycline in aqueous solution, comprising admixing in a tetracycline containing solution a chelating agent at a concentration of about 0.1-0.5% and an antioxidant at a concentration of about 0.1-0.5% and, as necessary, adjusting the pH of the solution so that it is between about 4.5 and about 7.5 is also disclosed. Tetracycline compositions of the invention may be used to treat inflammatory and/or tissue degeneration conditions. | 2012-02-02 |
20120028930 | FLUPIRTINE SALTS AND POLYMORPHS - The present invention includes salts and polymorphs of flupirtine including, but not limited to carboxylic acid salts and sulfonic acid salts and their polymorphs. The present invention also includes pharmaceutical compositions comprising the salts and polymorphs of flupirtine. The invention also relates to the therapeutic use of the flupirtine salts and polymorphs to treat nervous system disorders, pain disorders, musculoskeletal disorders, and other diseases and conditions. | 2012-02-02 |
20120028931 | HETEROCYCLIC M-GLU5 ANTAGONISTS - Compounds I | 2012-02-02 |
20120028932 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS - The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. | 2012-02-02 |
20120028933 | Cell Culture Media Supplement and Method of Molecular Stress Control - A novel class of agents has been identified to serve as cell-guard agents and/or target-specific supplements to increase cell quality and yield, as well as select for target cell populations. Laboratory experiments have demonstrated the use of cell-guard agents and/or target-specific supplements in the bioprocessing of cells as well as in selecting out a desired cell population. Several potential additive agents (both natural and synthetic) have been identified during these studies, including Vitamin D | 2012-02-02 |
20120028934 | STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D-CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY - Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of making such compositions, and methods for treating psoriasis using such compositions. | 2012-02-02 |
20120028935 | Therapeutic Gestagens for the Treatment of Premenstrual Dysphoric Disorder - A method of treating premenstrual dysphoric disorders comprising administering to a patient in need of such treatment daily from day 1 to day 24 3 mg of drospirenone and 0.02 mg of ethinylestradiol. | 2012-02-02 |
20120028936 | ORAL CONTRACEPTION WITH TRIMEGESTONE - The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is more than 500 μg. | 2012-02-02 |
20120028937 | CYCLIC AMINE-1-CARBOXYLIC ACID ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Provided is a compound useful as a therapeutic drug for pain and inflammation caused by various pathological conditions such as neuropathic pain and rheumatoid arthritis. The compound of the formula (I) or a salt thereof [wherein R | 2012-02-02 |
20120028938 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS - The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, | 2012-02-02 |
20120028939 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS - The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, | 2012-02-02 |